Sugi Predict

Sugi Predict / Compounds / SCHEMBL29629184

SCHEMBL29629184

SCHEMBL29629184

O=C1c2ccccc2C(=O)c2oc(-c3ccccc3)nc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP1 O94782 4/20 1.00
▸ USP19 O94966 2/20 1.00
▸ WDR48 Q8TAF3 1/20 1.00
▸ UCHL3 P15374 1/20 0.77
▸ USP2 O75604 2/20 0.73
▸ USP8 P40818 2/20 0.73
▸ OTUB1 Q96FW1 2/20 0.73
▸ USP36 Q9P275 1/20 0.73
▸ ELANE P08246 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ ALDH1A1 P00352 5/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ IDO1 P14902 1/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ AHR P35869 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7808226 1.00 USP1 (1.00) USP1USP19WDR48UCHL3USP2
SCHEMBL29629183 1.00 USP1 (1.00) USP1USP19WDR48UCHL3USP2
SCHEMBL19220486 0.90 USP1 (0.82) USP1USP19WDR48UCHL3USP2
SCHEMBL18347790 0.88 USP1 (0.79) USP1USP19WDR48UCHL3USP2
SCHEMBL18203587 0.88 USP1 (0.79) USP1USP19WDR48UCHL3USP2
SCHEMBL7968066 0.87 USP1 (0.77) USP1USP19WDR48UCHL3USP2
SCHEMBL7815859 0.87 USP1 (1.00) USP1USP19WDR48UCHL3USP2
SCHEMBL7808410 0.87 USP1 (0.77) USP1USP19WDR48UCHL3USP2
SCHEMBL31276578 0.87 USP1 (1.00) USP1USP19WDR48UCHL3USP2
SCHEMBL19225117 0.87 USP1 (0.77) USP1USP19WDR48UCHL3USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130910-A1 METHODS OF TREATING CANCERS DANA FARBER CANCER INST INC (US) 2026-05-14 — — US claimed
EP-3703669-B1 USP1 OR UAF1 INHIBITORS FOR USE IN TREATING CANCER DANA FARBER CANCER INST INC (US) 2025-08-06 — — EP claimed
US-12263166-B2 Methods of treating cancers having a BRCA1 and/or BRCA2 mutation(s) DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-04-01 — — US claimed
CN-114617879-B Use of SJB2-043 as medicine for inhibiting glioblastoma 中国人民解放军陆军军医大学第一附属医院 2023-09-05 — — CN claimed
US-20230093238-A1 METHODS OF TREATING CANCERS DANA-FARBER CANCER INSTITUTE, INC. 2023-03-23 — — US claimed
US-11413288-B2 Methods of treating cancers DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-08-16 — — US claimed
CN-114617879-A Application of SJB2-043 as drug for inhibiting glioblastoma 中国人民解放军陆军军医大学第一附属医院 2022-06-14 — — CN claimed
US-20260130910-A1 METHODS OF TREATING CANCERS DANA FARBER CANCER INST INC (US) 2026-05-14 — — US disclosed
US-20260024617-A1 METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES SCIPHER MEDICINE CORP (US) 2026-01-22 — — US disclosed
EP-3703669-B1 USP1 OR UAF1 INHIBITORS FOR USE IN TREATING CANCER DANA FARBER CANCER INST INC (US) 2025-08-06 — — EP disclosed
CN-118903428-B Application of USP1 inhibitor in preparation of medicine for enhancing STING-mediated antitumor immunity 暨南大学附属第一医院（广州华侨医院） 2025-05-30 — — CN disclosed
US-12263166-B2 Methods of treating cancers having a BRCA1 and/or BRCA2 mutation(s) DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-04-01 — — US disclosed
CN-118903428-A Application of USP1 inhibitor in preparation of medicine for enhancing STING-mediated antitumor immunity 暨南大学附属第一医院（广州华侨医院） 2024-11-08 — — CN disclosed
CN-114617879-B Use of SJB2-043 as medicine for inhibiting glioblastoma 中国人民解放军陆军军医大学第一附属医院 2023-09-05 — — CN disclosed
CN-114617879-B Use of SJB2-043 as medicine for inhibiting glioblastoma 中国人民解放军陆军军医大学第一附属医院 2023-09-05 — — CN disclosed
US-20230093238-A1 METHODS OF TREATING CANCERS DANA-FARBER CANCER INSTITUTE, INC. 2023-03-23 — — US disclosed
US-11413288-B2 Methods of treating cancers DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-08-16 — — US disclosed
CN-114617879-A Application of SJB2-043 as drug for inhibiting glioblastoma 中国人民解放军陆军军医大学第一附属医院 2022-06-14 — — CN disclosed
CN-114617879-A Application of SJB2-043 as drug for inhibiting glioblastoma 中国人民解放军陆军军医大学第一附属医院 2022-06-14 — — CN disclosed
CN-114617879-A Application of SJB2-043 as drug for inhibiting glioblastoma 中国人民解放军陆军军医大学第一附属医院 2022-06-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11413288-B2 Methods of treating cancers BRCA1, TP53, BAP1 USP1 6/4885USP19 89/4885WDR48 908/4885
US-12263166-B2 Methods of treating cancers having a BRCA1 and/or BRCA2 mutation(s) BRCA1, TP53, BAP1 USP1 7/4885USP19 54/4885WDR48 894/4885
US-20260130910-A1 METHODS OF TREATING CANCERS BRCA1, PARP3, PARP2 USP1 14/4885USP19 23/4885WDR48 1636/4885
US-20230093238-A1 METHODS OF TREATING CANCERS BRCA1, TP53, BAP1 USP1 6/4885USP19 89/4885WDR48 908/4885
US-20260024617-A1 METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES SET, SSB, CNKSR1 USP1 526/4885USP19 425/4885WDR48 1519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.